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Abstract
Herpes labialis is a common skin infective condition, worldwide, which is primarily caused by
HSV-1. Recurrent episodes of herpes labialis, also known as cold sores, can be frequent, painful,
long-lasting and disfiguring for infected patients. At present, there are two types of antivirals for
the treatment of herpes labialis, topical and oral, which are available over the counter or as
prescription-only. The aim of antiviral therapy is to block viral replication to enable shortening the
duration of symptoms and to accelerate healing of the lesions associated with herpes labialis. This
review examines the evidence for the effectiveness of current topical and oral antivirals in the
management of recurrent episodes of herpes labialis. In most countries, oral antivirals for herpes
labialis are available as prescription-only. However, in early 2010, the oral antiviral famciclovir
was reclassified from prescription-only medicine to pharmacist-controlled status in New Zealand.
The benefits and risks associated with moving an antiviral therapy for herpes labialis from
prescription-only to pharmacist-controlled status are reviewed here, and the implications for
patients, general physicians and pharmacists are considered.
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Herpes labialis is a common condition worldwide. The primary cause is HSV-1, but the
epidemiology has changed dramatically in recent decades. HSV-1 infection was traditionally
acquired in childhood and adolescence through non-sexual contact but is now becoming the
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most common cause of primary genital HSV infections.1 At least 50% of new cases of
herpes genitalis in developed countries are now caused by HSV-1.2 Although HSV-2 more
commonly causes recurrent herpes genitalis,3,4 it has been identified as a cause of
oropharyngeal infection and herpes labialis5. The prevalences of HSV-1 and HSV-2 are
generally higher in developing than in developed regions of the world,6,7 but seroprevalence
rates are declining for both HSV-1 and HSV-2 in the USA.7 In eastern European countries
(most notably Bulgaria), the seroprevalences of HSV-1 and HSV-2 are higher than in more
northern European countries (England and Wales, Germany, Netherlands, Belgium and
Finland).8 In Australia, a nationwide population-based survey reported HSV-1 and HSV-2
seroprevalences of 76% and 12%, respectively, in 1999–2000, being higher in women
(80.4% and 16.3%, respectively) than in men (71.3% and 8.9%, respectively) and rising to
77.3% and 16.4%, respectively, in the 35–44-year age group.9 Higher socioeconomic status
is associated with a lower prevalence of HSV-15 and cross-sectional evaluations have
identified risk factors for herpes labialis including female gender, older age (65–74 years),
white race/ethnicity, frequent upper respiratory infections and low lymphocyte counts.9,10
Smokers report fewer herpes labialis outbreaks than nonsmokers.10
Primary HSV-1 infection can be either asymptomatic or cause self-limiting
gingivostomatitis in the immunocompetent host.11 The virus establishes latency in the
sensory ganglia and, when reactivated, causes herpes labialis. Reactivation stimuli include
exposure to ultraviolet light,12,13 fever,12 psychological stress14 and menstruation.15
Recurrent episodes of herpes labialis can be frequent, painful, long-lasting and
disfiguring.5,16 In immunocompromised patients, episodes are usually longer and more
severe, potentially involving the oral cavity or extending across the face.5,17 The prodrome
(symptoms of reactivation) is associated with itching, burning and/or paraesthesia prior to
the appearance of erythema and papule formation.17 Clinical progression evolves through
the development of a vesicle, pustulation, ulceration and, ultimately, scabbing. Peak viral
titres occur in the first 24 h after lesion onset, when most lesions are in the vesicular stage,
with a subsequent progressive decline as most lesions are converted to ulcers/crust.17,18
The aim of antiviral therapy is to block viral replication in order to enable shortening the
duration of symptoms and accelerate the resolution of lesions. Since the natural healing
process starts within the first 24 h of onset of an episode, if treatment is either warranted or
requested, it is imperative that therapy is initiated as soon as possible to ensure an optimal
therapeutic beneficial effect.19 Two categories of antivirals are available for treatment of
herpes labialis: topical and oral therapies. In this review, we examine these therapies for
herpes labialis available OTC and as prescription-only, and analyse the benefits and risks
associated with moving an antiviral therapy from prescription-only to pharmacist-controlled
status.
1. Current diagnosis and management of herpes labialis
Diagnosis of herpes labialis by GPs is usually based on the patient history of this condition,
the clinical signs and symptoms. Laboratory confirmation, however, may be required in
immunocompromised patients if the clinical presentation is atypical.
Many patients neither require nor use any treatment because the disease is self-limiting.20
For individuals with frequent recurrences, application of a sunscreen or zinc oxide to
decrease the probability of recurrent outbreaks may help.21,22 Some resort to alternative
therapies available OTC for prophylaxis and/or treatment, such as herbal-based products and
dietary supplements, despite unproven efficacy,23,24 or use OTC topical anaesthetics,
analgesics, antipyretics, antiseptics and emollients. For many, however, the pain, unaesthetic
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and embarrassing appearance, and the social stigma warrant using approved antiviral
therapy (Table 1).
A recent metaanalysis found that the therapeutic effectiveness of OTC topical anaesthetic
agents and zinc-based creams in treating herpes labialis is inconclusive due to limited
evidence.21 OTC topical antiviral therapies applied numerous times a day for up to 5 days
are widely used. Clinical studies have shown that these products provide a small clinical
benefit by reducing the duration of symptoms.21 Patients with particularly severe, frequent
or complicated disease require early treatment and may also benefit from a chronic
prophylaxis with a licensed systemic drug that is approved for the indication. Topical
antivirals are not effective prophylactically,25 because topical application will not get the
drug to the site of reactivation.
Topical antiviral medication does not impact the host immune response and consequent
inflammatory cascade, but the co-administration of a topical corticosteroid may limit the
inflammation.26–28 An experimental topical combination of aciclovir and hydrocortisone has
proved to confer clinical benefit, but the need for frequent application (five or six times
daily) would make it less convenient than high-dose, short-course oral antiviral therapy.29 A
controlled trial showed that aciclovir/hydrocortisone cream significantly reduced the
frequency of both ulcerative and nonulcerative recurrences in immunocompetent adults and
adolescents.28
For therapy of the initial outbreak of herpetic gingivostomatitis, oral aciclovir is of some
benefit,21 by reducing the time to healing.30 The FDA, however, has not approved any
antiviral agent for initial primary gingivostomatitis. For treatment of recurrent herpes
labialis, a metaanalysis of five placebo-controlled and two dose-comparison studies
evaluating aciclovir, famciclovir or valaciclovir indicates that oral antiviral therapy
decreases outbreak duration and the associated pain by 1 day.31 However, none of the
studies were head-to-head comparisons. Short-course, high-dose antiviral therapy offers
greater patient and physician convenience,25 are cost beneficial,25,32 and may improve
patient adherence.32
2. Risks versus benefits of reclassification of antiviral therapy
Despite the recent publication of an evidence-based review suggesting that oral antiviral
agents are more beneficial than topical agents for treating recurrent episodes,21 antiviral
tablets are currently only available by prescription (POM or Rx only) in most countries.
Availability would be facilitated by a product being reclassified as a pharmacy-only
(pharmacist-controlled) medicine. This is defined as a product that can be obtained without a
prescription provided that a pharmacist is present at the time of sale and that the drug is
controlled by the pharmacist following a patient's request. The pharmacist can query the
patient to ensure that the medication is both warranted and correctly used for herpes labialis.
This approach should save the patient's time and offers greater convenience, as well as
affording greater personal responsibility in the therapeutic choice and early administration of
the drug as first symptoms occur during the brief window of therapeutic opportunity.33,34
Furthermore, a physician's time spent in consultations and writing prescriptions may be
reduced.33
However, there are four main factors that should be considered when reclassifying a therapy
from a prescription-only status to a pharmacy-only or OTC medicine: evidence of efficacy;
documented safety; probability of the development of resistance; and on-going monitoring.
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The US FDA has approved short-course regimens of valaciclovir and famciclovir as
prescribed oral treatments for recurrent herpes labialis30 based on efficacy results
summarized in Table 2 and Fig. 1. The approval of short-course oral therapy regimen for
herpes labialis is a reflection of the trend towards greater convenience and resource
management in medicine, with healthcare providers, patients and payers all potentially
benefiting. Such treatments are now recommended for recurrent herpes labialis having
shown that they can accelerate healing and decrease pain.32,34 In addition, suppressive oral
aciclovir,21,22 famciclovir35 and valaciclovir22 have all been shown to be effective for the
management of severe, frequent or complicated disease.
If there is a greater ease of access to oral antiviral therapy as a result of a change to
pharmacy-only status, patients may initiate therapy earlier in the course of the illness and, as
a result, the treatment should be more effective.34 In addition, patient-initiated episodic
therapy of recurrent herpes labialis may even prevent lesion development.34 However, it
should be noted that there are no data on the effectiveness of early versus delayed antiviral
therapy on herpes labialis lesions because no randomised controlled trials comparing these
strategies in herpes labialis have been performed to date.
2.2. Safety
Clinical studies evaluating the safety of oral aciclovir, famciclovir and valaciclovir for
treatment of herpes labialis have indicated that these agents are generally well tolerated and
associated with minimal adverse events in patients.
The number of adverse events and drug-related adverse events was similar in a head-to-head
trial of valaciclovir (1-day and 2-day therapy) vs placebo for herpes labialis.36 Headache
was more common with valaciclovir than with placebo, but other adverse events, such as
nausea and diarrhoea, in addition to a small number of cases of dyspepsia, dry mouth and
flatulence, were recorded in all three treatment arms.36 No serious adverse events were
reported.36 Data pooled from two identical trials of valacyclovir 500 mg (n = 49) versus
placebo (n = 49) once daily for 16 weeks revealed a slightly higher incidence of adverse
events in the placebo (29 events, 39% of patients) than in the valacyclovir arm (22 events,
33% of patients).37 In a more recent study comparing the combination of oral valacyclovir 2
g twice daily for 1 day and topical clobetasol gel 0.05% twice daily for 3 days with placebo,
the adverse events reported were mild and infrequent.27
A randomized, placebo-controlled trial of episodic famciclovir treatment in adults found that
the adverse events were similar in the placebo and two famciclovir arms (1500 mg once a
day for 1 day or 750 mg twice a day for 1 day). The adverse events, headache and nausea,
were mild-to-moderate in intensity,38 occurring in <10% and <4% of patients, respectively,
in each treatment group. These safety data for famciclovir support the findings from an
earlier dose-ranging study in which patients received 125 mg, 250 mg, or 500 mg of
famciclovir or placebo 3 times per day for 5 days initiated 48 h after UVR exposure.39 There
were no statistically significant differences in incidence of headaches and nausea reported
by patients across the four treatment groups and no serious adverse events.39 In adolescents
with herpes labialis treated with famciclovir in an open-label study, adverse events were
generally mild and transient.40
The importance of prompt use and/or the need for rapid relief of symptoms has been
recognized by the reclassification of certain medicines. Some examples are provided in
Table 3. These products have been deemed sufficiently safe based on post-marketing studies
not to require a doctor consultation. However, patients still need to be advised by a
pharmacist; a key requirement of the regulatory authorities is that the manufacturers of drugs
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reclassified to OTC status must show that they are providing adequate training and
education for both patients and pharmacists. A post-marketing surveillance program for oral
antiviral agents will help in collating data on adverse events related to the use of these
therapies.
2.3. Resistance
Despite the increasing use of HSV-specific antiviral agents for recurrent herpes labialis in
the past 20 years, as well as a variety of other herpesvirus infections, the incidence of
resistant HSV-1 strains remains low (<0.5% in the immunocompetent host for the
commonly used anti-HSV-1 agents).41–44 In immunocompromised patients, although higher
than in immunocompetent patients, rates of resistance are still low: aciclovir 7% vs <0.5%45
and penciclovir 2.1% vs 0.22%, respectively.43 Furthermore, analysis of herpes simplex
isolates from immunocompetent patients with frequently recurring herpes genitalis who
stopped successful suppressive aciclovir therapy after 6 years showed that there was no
selection for resistance.46 Thus, while a concern, it is unlikely that development of
resistance to oral antiviral agents when used episodically in immunocompetent patients will
occur.
2.4. On-going monitoring
Although not much is known about how often people obtain prescription drugs from online
pharmacies, a substantial number of patients appear willing to accept considerable risk from
off-label use to gain greater access to medication.47 The potential for accidental, or
deliberate, misuse of the agent across a wider range of clinical conditions needs to be
addressed and monitored.
The oral antiviral agents used for herpes labialis (aciclovir, famciclovir and valaciclovir) all
have POM approval for herpes genitalis,48–50 albeit usually at different dosage regimens.
Despite the introduction of pharmacist controls, some might deliberately use OTC oral
antiviral agents intended for treatment of herpes labialis to treat herpes genitalis, because of
the stigma associated with the latter.51 A key concern is that the patient with genital herpes
would miss the opportunity to receive correct and valuable medical advice, thus perhaps
increasing risks of transmission and complications. Short-course therapy with some agents,
using similar regimens to those for herpes labialis, has been investigated for the treatment of
recurrent herpes genitalis and has been shown to be as safe as the traditional longer courses
of therapy.52–54 These therapies, however, have yet to receive approval in most countries
with only a few countries, such as Australia (single 500 mg dose, followed by three doses of
250 mg famciclovir for genital herpes) and the US (250 mg of famciclovir twice daily for
suppression of recurrent episodes of genital herpes), where a short course of famciclovir has
been approved. Thus, patients buying an OTC herpes labialis treatment to use for herpes
genitalis treatment would be unlikely to suffer an adverse event. The small amounts of
medication that are permitted when obtained OTC reduce the potential for overdosing, and
most patients always or often following the directions on the OTC package insert.55
Incorrect patient's self-diagnosis, concurrent disease and non-disclosed co-medications are
important concerns that should be addressed when a pharmacist advises patients seeking
OTC medication. Other concerns, such as dosing adherence issues, are not specific to the
OTC medication. The experience with OTC antibacterial agents have shown that education
and product labelling are essential to the success of reclassification.56 Ensuring the correct
diagnosis and establishing patient history is necessary for the correct treatment to be sold.
Pharmacist education through training, continuing professional development and suitable
approved protocols will improve pharmacy resources.56 All information provided should be
consistent and relevant, and linked to additional resources so that pharmacists can refer
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patients to if they need further information.56 Patient education using targeted campaigns are
specifically recommended for HSV, stressing the importance of initiating treatment during
the prodrome phase.57
Lessons can also be learnt from the New Zealand experience. Reclassification of famciclovir
from a POM to a restricted medicine was recommended at the 42nd meeting of the New
Zealand Medicines Classification Committee.58 Pharmacist-controlled purchase of oral
famciclovir for the treatment of herpes labialis was approved in early 2010. The
transTasman therapeutic products agency agreement between New Zealand and Australia is
likely to result in the rescheduling of famciclovir to a pharmacist-only medicine in Australia
too. Based on the acceptability of reclassification of oral famciclovir in New Zealand, it is
likely that the same will be sought in the rest of the world for famciclovir and the other oral
antivirals. It should be noted that these moves towards OTC are being made for therapies
marketed exclusively for herpes labialis, and not herpes genitalis. Indeed, a submission to
switch aciclovir for herpes genitalis to OTC status was not supported in the USA.59
3. Pharmaco-economic benefits of OTC therapies
Generally, OTC therapies are more accessible and convenient than prescription medications
and are usually cheaper because they are often generic.60 In some countries, patients may
have to pay the full cost of a POM but, in others, patients may only have to pay a fixed
prescription charge that could be the same or less than the OTC price. The change from
POM to OTC status of medications has been the direction followed by more than 700
treatments over the past 30 years and has led to annual healthcare cost savings of over $20
billion for US consumers.61 For example, the switch from POM to OTC status for topical
hydrocortisone saved US consumers $200 million in the first year and $400 million in the
second, taking into account both the direct and indirect costs.60,62 In Europe, switching
appropriate medicines for the treatment of minor illnesses to OTC could realise an annual
saving of € 16 billion.63 In allergic rhinitis,64 migraine,65 emergency contraception66 and
weight control,67 marked cost savings are achievable.
4. Conclusions
Initial diagnosis of herpes labialis should be made by GPs. With patient education,
thereafter, a significant reduction in a GP's work burden, as well as cost-savings for both the
patient and the GP, could result from the availability of pharmacy-controlled antiviral
medication for herpes labialis. Another important consideration is reducing the delay in the
start of treatment, with patients being able to self-medicate as soon as they feel the prodrome
of a herpes labialis outbreak. Suitable safeguards need to be in place, such as the monitoring
for safety and appropriate package labelling of the medication. In addition, if there is a
change from prescription-only to pharmacy-only status for antiviral agents in the treatment
of herpes labialis, surveillance systems should be in place to assess the impact on treatment
of genital herpes.
Pharmacist and patient education on the efficacies of systemic and topical antiviral agents,
and the importance of treatment adherence to prevent the emergence of resistance are
essential. Although systemic agents have proved to be highly efficacious in the treatment of
herpes labialis based on data from placebo-controlled trials, randomized-controlled trials
directly comparing systemic versus topical therapies are required. The benefits also need to
be communicated at the governmental and/or payer levels, using the experience with other
OTC medications as examples, as well as the recent reclassification of famciclovir for
herpes labialis in New Zealand.
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Efficacy of short-course famciclovir and valaciclovir in the treatment of herpes labialis.
Famciclovir 1500 mg single dose for 1 day significantly reduced time to healing of primary
vesicular herpes labialis lesions.38 *p < 0.001 vs placebo; †vesicular lesions; ‡Normal skin
defined as loss of crust, swelling, and dry flaking for all lesions (vesicular and aborted).
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Table 1
Antiviral agents approved for treatment of herpes labialis in the UK and USA.
Antiviral agent [trade name] Dosing schedule Manufacturer Country (legal status)
Penciclovir cream (1%)
[Fenistil® Cold Sore Cream68;
Denavir®,69]
Approximately 8 times daily
(2- hourly intervals) during









Approximately 5 times daily
(3–4 hourly intervals) during





Famciclovir [Famvir®,49] 1500 mg as a single dose Novartis Pharmaceuticals Corporation USA (Rx only)
Valaciclovir (Valtrex®,50) 2 g every 12 h for 1 day GlaxoSmithKline USA (Rx only)
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Table 2
Summary of studies examining effectiveness of oral antiviral agents for management of recurrent herpes
labialis outbreaks.
Study design N Outcome
Aciclovir
400 mg twice daily, 12 h before ultraviolet exposure
vs placebo21,71
147 Aciclovir reduced frequency of attacks and duration of symptoms overall (p
<0.05)
Fewer lesions with aciclovir (7%) vs placebo (26%)
400 mg 5 times daily for 5 days vs placebo taken
during tingling stage21,72
174 Shorter duration of symptoms with aciclovir (8.1 days) vs placebo (12.5 days)
(p =0.02)
Mean duration of pain shorter with aciclovir (2.5 days) vs placebo (3.9 days)
(p = 0.02)
800 mg twice daily for 3–7 days vs placebo73 237 No significant difference in lesion occurrence with aciclovir vs placebo
200 mg 5 times daily for 5 days vs placebo taken
within 12 h of the onset of the first episode21,74
149 No significant difference in healing time or pain duration with aciclovir vs
placebo
400 mg twice daily for 4 months vs placebo75 20 Longer median time to recurrence with aciclovir (118 days) vs placebo (46
days) (p = 0.05)
53% fewer clinical recurrences with aciclovir vs placebo (p = 0.009)
Valaciclovir
500 mg once daily for 4 months vs placebo21,37 98 Significantly longer mean time to recurrence with valaciclovir (13.1 weeks)
vs placebo (9.6 weeks) (p = 0.016)
More patients were recurrence-free with valaciclovir (60%) vs placebo (38%)
(p = 0.041)
2 g twice daily for 1 day vs 2 g twice daily on Day 1,
then 1 g twice daily on Day 2 vs placebo21,36
954 Shorter median duration of episode with 1-day valaciclovir (5.0 days; p <
0.001) and 2-day valaciclovir (4.5 days; p = 0.009 vs placebo) vs placebo (5.0
days)
2 g twice daily for 1 day vs 2 g twice daily on Day 1,
then 1 g twice daily on Day 2 vs placebo21,36
902 Shorter median duration of episode with 1-day valaciclovir (4.0 days; p <
0.001 vs placebo) and 2-day valaciclovir (4.5 days; p = 0.009 vs placebo) vs
placebo (5.0 days)
Famciclovir
125, 250 or 500 mg, 3 times daily for 5 days vs
placebo39
248 No significant difference in number of lesions between four groups.
Famciclovir 500 mg reduced median time to healing (4 days) vs placebo (6
days; p = 0.010).
Reduced mean lesion size in all famciclovir groups in a dose-proportional
manner vs placebo
1500 mg single dose for 1 day vs 750 mg twice daily
for 1 day vs placebo38
701a Reduced median healing times of primary lesions with single-dose
famciclovir (4.4 days; p < 0.001 vs placebo) twice-daily famciclovir (4.0
days; p < 0.001 vs placebo) vs placebo (6.2 days)
a
Analysis only included the 477/701 (68%) of participants who subsequently developed vesicular herpes labialis lesions during the course of
treatment.
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Table 3
Examples of drugs that have switched prescribing status in the UK.
Drug Indication Legal status
Chloramphenicol (1%) eyedrops Treatment of acute bacterial conjunctivitis Pharmacist-controlled
Levonorgestrel Emergency contraception in women aged 16 years and over76 Pharmacist-controlled
Azithromycin Treatment of known or suspected asymptomatic Chlamydia trachomatis genital
infection in adults 16 years and over77
Pharmacist-controlled
Diclofenac potassium (oral) For short-term relief of headache, backache, dental pain, period pain, rheumatic
and muscular pain, cold and flu symptoms
OTC
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